Skip to main
AORT
AORT logo

Artivion (AORT) Stock Forecast & Price Target

Artivion (AORT) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Artivion Inc has demonstrated a notable increase in operating margin, reaching 17.8%, which reflects a significant year-over-year improvement of 770 basis points, surpassing previous estimates. The company anticipates ongoing growth prospects with expected enhancements in gross margin and EBITDA margins for 2025, supported by an increase in research and development investments. Strong sales growth across its key product lines, including aortic stent grafts and On-X products, along with the potential revenue boost from the upcoming AMDS product launch, further underpins a positive outlook for Artivion's financial performance.

Bears say

Artivion Inc is facing several significant challenges that contribute to a negative outlook on its stock. The company's fourth-quarter revenue growth declined to 3.5%, a decrease from 9.5% in the previous quarter, primarily due to a cybersecurity incident that resulted in a revenue headwind of approximately $4.5 million, exceeding the quarterly revenue miss of $3.5 million. Furthermore, the bear case scenario suggests that revenue growth may slow to mid- to high-single digits, driven by disappointing product launches and underwhelming international expansion, alongside a reduction in gross margin of 200 basis points year-over-year.

Artivion (AORT) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artivion (AORT) Forecast

Analysts have given Artivion (AORT) a Buy based on their latest research and market trends.

According to 8 analysts, Artivion (AORT) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artivion (AORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.